GUEST COLUMNISTS

• Safe And Sustainable DCTs and Hybrid Trials (Part 2)

  In part two of this series, learn practical cloud architectural patterns, governance structures, and operating mechanisms that allow sponsors to run hybrid and decentralized trials.

• Why Sponsors Should Share KPI Rationale With Sites

  To build partnerships, foster transparency, and promote shared accountability, Curo Research CEO Amy Bland explains why sponsors need to communicate the utility of KPIs with sites.

• Rethinking Clinical Trials In Rare Neurodegenerative Diseases: Lessons From Alterity's MSA Trial

  Alterity Therapeutics CEO David Stamler shares how early diagnosis, biomarker-guided design, and precise patient selection positively impacted a trial in multiple system atrophy (MSA).

• Breaking Through Tumor Defenses With Next-Generation Cell Therapy

  Ernexa Therapeutics CEO Sanjeev Luther shares how clinical research has revealed why certain cancers resist treatment and how emerging cell therapies may help break through those defenses.

• Reprogramming The Tumor Microenvironment: Bringing A Metabolic Checkpoint Therapy Into The Clinic

  Pilatus Biosciences CEO Raven Lin shares learnings from his company's early-stage oncology program.

• Time Is Lives: How Collaboration And Urgency Are Rewriting The Future Of Rare Disease

  The inflection point has arrived, says Rob Freishtat, MD, MPH. Understand how collaboration will rewrite how we think of rare disease clinical research.

• The Problem With Excluding Children From GLP-1 Trials In The U.S.

  In the U.S., roughly 15 million children are obese. But many are excluded from GLP-1 research. Obesity expert Evan Nadler, MD, explains why that's problematic.

• U.S. Pharma Tariffs And MFN In 2026: Manufacturing And Procurement Impact

  Beroe Inc.'s Mathini Ilancheran discusses the 2025 U.S. pharma tariff framework and translates it into actionable procurement and outsourcing responses.